Abstract: The disclosure relates to the field of medicinal chemistry. Disclosed are a 14-chloro-?-elemene nitric oxide donor derivative and a preparation method and use thereof in the preparation of anti-tumor drugs. The 14-chloro-?-elemene nitric oxide donor derivative has a general formula shown in formula (I): in formula (I): R1 represents a linear or cyclic alcohol amine structure containing nitrogen and oxygen atoms; and each of R2 and R3 is independently selected from the group consisting of C1-10 alkyl, C3-12 cycloalkyl, C6-12 aryl, 5- to 10-membered cyclic heteroaryl, C2-10 alkenyl, C2-10 alkynyl, and C2-10 alkoxy.

Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

Abstract: Compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC are described. Specifically, the compounds represented by the following formula (I) are described, wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an anti-tumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the anti-tumor response rate of the antibody and broaden the types of tumors to be treated.

Abstract: The invention provides compounds of formula (I) as shown below, including their possible enantiomers and diastereomers, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers).

Abstract: The invention provides compounds of formula (I) as shown below, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers).

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: A circuit breaker includes: first and second contacts moveable relative to each other along an axis of the circuit breaker between an open and closed configuration and defining an arcing region in which an arc is formed during current breaking operation; a nozzle directing a flow of quenching gas onto the arcing region during current breaking operation, a diffusor downstream of the nozzle for further transporting the quenching gas within the arcing region and/or downstream of the arcing region, and a mechanical swirling device arranged downstream of the nozzle and at least partially in the diffusor for imparting a swirl onto the quenching gas flowing along the diffusor, the mechanical swirling device having an axial overlap with the second contact in the open configuration of the circuit breaker.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: A circuit breaker includes: first and second contacts moveable relative to each other along an axis of the circuit breaker between an open and closed configuration and defining an arcing region in which an arc is formed during current breaking operation; a nozzle directing a flow of quenching gas onto the arcing region during current breaking operation, a diffusor downstream of the nozzle for further transporting the quenching gas within the arcing region and/or downstream of the arcing region, and a mechanical swirling device arranged downstream of the nozzle and at least partially in the diffusor for imparting a swirl onto the quenching gas flowing along the diffusor, the mechanical swirling device having an axial overlap with the second contact in the open configuration of the circuit breaker.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: Compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC are described. Specifically, the compounds represented by the following formula (I) are described, wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an anti-tumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the anti-tumor response rate of the antibody and broaden the types of tumors to be treated.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.

Abstract: A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.

Abstract: An electric switching device filled with a dielectric insulating medium includes first and second arcing contact, first exhaust volume downstream of first arcing contact and second exhaust volume downstream of second arcing contact. The exhaust volumes includes several first openings in their walls, through which the insulating medium exits into third volume. The third volume is arranged around the first or second exhaust volume and is radially delimited by the wall of the exhaust volumes and by an exterior wall having second openings through which the insulating medium exits the third volume. One baffle device is provided inside third volume such that vortex flow of the insulating medium is generated when it passes the baffle device on its way towards the second openings. Turbulent flow conditions are chosen such that gravitational force allows to trap or contributes to trap particles in the baffle device.

Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.

Abstract: An electric switching device filled with a dielectric insulating medium includes first and second arcing contact, first exhaust volume downstream of first arcing contact and second exhaust volume downstream of second arcing contact. The exhaust volumes includes several first openings in their walls, through which the insulating medium exits into third volume. The third volume is arranged around the first or second exhaust volume and is radially delimited by the wall of the exhaust volumes and by an exterior wall having second openings through which the insulating medium exits the third volume. One baffle device is provided inside third volume such that vortex flow of the insulating medium is generated when it passes the baffle device on its way towards the second openings. Turbulent flow conditions are chosen such that gravitational force allows to trap or contributes to trap particles in the baffle device.

Abstract: An electrical switching device is filled with a dielectric insulating medium comprising an organofluorine compound, in particular a fluoroether, a fluoroarnine, a fluoroketone or a fluoroolefin, and comprises at least an arcing contact arrangement with a first arcing contact and a mating second arcing contact. At least a first intermediate volume is provided downstream from the first arcing contact, and/or at least a second intermediate volume is provided downstream from the second arcing contact. The intermediate volumes are for intermediate pressure enhancement and exhaust gas jet formation for turbulent convective heat transfer to metal walls of the exhaust system. In embodiments, the first and/or second intermediate volume is delimited by at least one moveable wall arranged transversally to the longitudinal axis and shiftable parallel to it by an actuation device.

Abstract: An electrical switching device is filled with a dielectric insulating medium comprising an organofluorine compound, in particular a fluoroether, a fluoroamine, a fluoroketone or a fluoroolefin, and comprises at least an arcing contact arrangement with a first arcing contact and a mating second arcing contact. At least a first intermediate volume is provided downstream from the first arcing contact, and/or at least a second intermediate volume is provided downstream from the second arcing contact. The intermediate volumes are for intermediate pressure enhancement and exhaust gas jet formation for turbulent convective heat transfer to metal walls of the exhaust system. In embodiments, the first and/or second intermediate volume is delimited by at least one moveable wall arranged transversally to the longitudinal axis and shiftable parallel to it by an actuation device.